New drug combo aims to control recurrent ovarian cancer
NCT ID NCT07454018
First seen Mar 10, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tests a new drug called iparomlimab/tuvonralimab (QL1706) combined with standard chemotherapy followed by olaparib in women with platinum-sensitive recurrent ovarian cancer. The goal is to see if this combination can help control the cancer and delay its return. About 45 women aged 18-75 with certain types of ovarian cancer that came back at least 6 months after last platinum chemo will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.